The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Wyn, hopefully you are not doing this :-)
https://www.youtube.com/watch?v=xrnwmU6Iu7w
Wyn, welcome to the Light Side, hope you just haven't had a dunt on the head or stuck a fork in the toaster :-)
https://www.youtube.com/watch?v=M9iYT3lhmd4
Just seen a sneak preview of a logged RNS
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, will host a Science Day for City analysts and fund managers on 23rd February 2023 to discuss recent progress within the Company's Therapeutics Division and hear from selected key opinion leaders in the field of oncology.
The event will include an additional update on the ongoing preclinical programmes as well as on progress in the ALS-6000-101 phase 1a clinical trial of AVA6000, Avacta's lead pre|CISIONTM tumour targeted chemotherapeutic, a modified form of the chemotherapy doxorubicin.
As previously stated via RNS, The Company are pleased to update the Market on progress in this study to date. In a nutshell AVA6000 is "Pure Dead Brilliant" also as previously promised several major inflection points will be reached over the coming months.
BF "In one of my posts last year, I mentioned the likely scenario that the Trail-related RNS is going to fall most likely this month, on or preferably before the 23rd.... according to my analysis of previous RNS trials and related RNS release dates"
Is that the "Trail of the Lonesome Pine" :-)
"is it us, leak, sujood knows, wouldn't want to be out of this over the weekend., there are more buys than sells, its MM again, casino AIM that's Corrupt, prints after hours"
Wyn, I totally agree with all that stuff you quoted above......It's definitely us and most definitely don't be out over the weekend anyone :-)
Big thanks Toukthe**** for that invaluable info, you’re an absolute genius in the investment world. You really are wasting your time here on LSE, the Motley Fool are constantly looking for people of your calibre ;-)